BRAF and metastatic malignant neoplasm in the lymph nodes: These cases often exhibited adverse clinicopathological features such as capsular invasion, lymphatic invasion, angioinvasion, minimal ETE, infiltrative and invasive capsule status, high AJCC pT stage, BRAF V600E mutations, TERT promoter mutations, lymph node metastasis, and synchronous metastasis [26].